ClinicalTrials.gg
Enrolling by invitationNCT04723940Updated Oct 8, 2026

Or v IV Antibiotics for Infection

A Phase 3 interventional study of Bactrim and Cefadroxil in Joint Infection, sponsored by Rothman Institute Orthopaedics. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Rothman Institute Orthopaedics · Phase 3, Interventional, and Treatment

How we know

Updated Oct 8, 2026Now Enrolling by invitationPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
308
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Management of periprosthetic joint infection (PJI) commonly includes 6 weeks of intravenous (IV) antibiotics after surgical treatment. However, there is little evidence to suggest that oral (PO) therapy results in worse outcomes. This study aims to determine whether or not PO antibiotics are non-inferior to IV antibiotics in treating PJI. The study is a multicenter, parallel-group, randomized (1 : 1), open-label, non-inferiority trial. The non-inferiority margin will be set at 10%. Adults with a clinical diagnosis of PJI according to the International Consensus Meeting (ICM) criteria who would ordinarily receive at least 6 weeks of antibiotics and have received ≤ 7 days of IV therapy from surgery will be included. A total of 308 participants will be centrally computer-randomized to PO or IV antibiotics to complete the first 6 weeks of therapy. Follow-on PO therapy will be permitted in either arm. The primary outcome is the proportion of participants experiencing treatment failure within 1 year. An associated cost-effectiveness evaluation including complications, resource utilization and quality-of-life data will be performed.

02

Conditions studied

  • Joint Infection
03

In context

Lead sponsor

Rothman Institute Orthopaedics is the lead sponsor of 119 studies on the registry; 18 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • aged ≥ 18 years
  • willing and able to give
  • primary THA or TKA diagnosed with PJI based on International Consensus Meeting criteria

    1. A sinus communicating with the prosthesis OR
    2. Two positive cultures obtained from the prosthesis OR
    3. 3 of 5 criteria:
  • Elevated ESR (>30mm/hr) and CRP (>10mg/L)
  • Elevated synovial leukocyte count (>3000 cells/µL) or change of ++ on leukocyte esterase strip
  • Elevated synovial neutrophil percentage (>80%)
  • One positive culture
  • Positive histological analysis of periprosthetic tissue (>5 neutrophils per high power field in 5 high power fields x400)
  • PJI treated by debridement and implant retention, or excision of the prosthetic joint (with or without planned reimplantation)
  • received ≤ 7 days of IV therapy after an appropriate surgical intervention

Exclusion criteria

Exclusion Criteria:

  • Previously treated for native septic arthritis or PJI in the same joint
  • S. aureus bacteremia on presentation or within the previous month
  • clinical, histological or microbiological evidence of mycobacterial, fungal or parasitic etiology of the infection
  • any other concomitant infection that, in the opinion of the clinician responsible for the patient, requires a prolonged course of IV antibiotic therapy (e.g. bacterial endocarditis, mediastinal infection, central nervous system infection)
  • septic shock or systemic features that, in the opinion of the clinician responsible for the patient, requires a course of IV antibiotic therapy (the patient could be re-evaluated if these features resolved)
  • an infection for which there are no suitable antibiotic choices to permit randomization between the two arms of the trial (e.g. when organisms are only sensitive to IV antibiotics or PO antibiotics)
  • unlikely to comply with trial requirements following randomization in the opinion of the investigator
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
308 participants (estimated)

Study arms

  • Active comparator
    Oral Antibiotics

    Participant will receive 6 weeks of oral antibiotic therapy to treat their infection. The type of antibiotic given will be at the discretion of the infectious disease doctor.

    Drug: Bactrim · Drug: Cefadroxil · Drug: Doxycycline Hcl · Drug: Clindamycin

  • Active comparator
    Intravenous Antibiotics

    Participant will receive 6 weeks of intravenous (IV) antibiotic therapy to treat their infection. The type of antibiotic given will be at the discretion of the infectious disease doctor.

    Drug: Bactrim · Drug: Cefadroxil · Drug: Doxycycline Hcl · Drug: Clindamycin

Interventions

06

What researchers measure

Primary outcomes

  1. Rate of Postoperative Infections

    The investigator will measure the incidence of postoperative infections in participants treated with oral antibiotics versus those treated with intravenous antibiotics

    Time frame: 2 years

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2021 (actual). Primary completion is estimated for Jan 2028, 84 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Jan 2023 → Jan 2028 and completion Jan 2023 → Jan 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2021
First posted
Jan 26, 2021
StartActual
Jan 25, 2021
Primary completionEst.
Jan 25, 2028was Jan 2023
CompletionEst.
Jan 25, 2028was Jan 2023
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Enrolling by invitation
changed Oct 8, 2026
Primary completion
Jan 25, 2023→Jan 25, 2028
Oct 8, 2026
Study completion
Jan 25, 2023→Jan 25, 2028
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Status unknown→Enrolling by invitation
    Primary completion Jan 25, 2023→Jan 25, 2028
    Study completion Jan 25, 2023→Jan 25, 2028
    + 4 other changes: verification date, oversight details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04723940
Responsible party
Sponsor
First posted
Jan 26, 2021
Start date
Jan 25, 2021
Primary completion
Jan 25, 2028 (estimated)
Completion
Jan 25, 2028 (estimated)
Last update
Oct 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cefadroxil · Doxycycline hydrochloride · Clindamycin

Start the discussion